Recursion Pharmaceuticals Inc (RXRX) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Recursion Pharmaceuticals Inc

NASDAQ | RXRX

5.50

USD

+0.18 (+3.38%)

AT CLOSE (AS OF Apr 17, 2025)

$2.2B

MARKET CAP

P/E Ratio

-1.69

EPS

$12

52 Week High

$3.8

52 Week Low

LIFE SCIENCES

Sector

RXRX Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

RXRX Technicals

Tags:

RXRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$14M
Total Revenue	$59M
Cost Of Revenue	$45M
Costof Goods And Services Sold	$45M
Operating Income	-$479M
Selling General And Administrative	$178M
Research And Development	$314M
Operating Expenses	$493M
Investment Income Net	-
Net Interest Income	$14M
Interest Income	$16M
Interest Expense	$1.6M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$36M
Income Before Tax	-$465M
Income Tax Expense	-$1.1M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$464M
Comprehensive Income Net Of Tax	-
Ebit	-$463M
Ebitda	-$427M
Net Income	-$464M

Revenue & Profitability

Earnings Performance

RXRX Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$1.4B
Total Current Assets	$714M
Cash And Cash Equivalents At Carrying Value	$594M
Cash And Short Term Investments	$594M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$734M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$336M
Intangible Assets Excluding Goodwill	$336M
Goodwill	$149M
Investments	-
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$71M
Other Non Current Assets	-
Total Liabilities	$414M
Total Current Liabilities	$187M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$22M
Total Non Current Liabilities	$226M
Capital Lease Obligations	$81M
Long Term Debt	$19M
Current Long Term Debt	$8.4M
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$108M
Other Current Liabilities	$82M
Other Non Current Liabilities	$4.7M
Total Shareholder Equity	$1B
Treasury Stock	-
Retained Earnings	-$1.4B
Common Stock	$4K
Common Stock Shares Outstanding	$274M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$359M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$36M
Capital Expenditures	$14M
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$304M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$464M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$14M
Total Revenue	$59M
Cost Of Revenue	$45M
Costof Goods And Services Sold	$45M
Operating Income	-$479M
Selling General And Administrative	$178M
Research And Development	$314M
Operating Expenses	$493M
Investment Income Net	-
Net Interest Income	$14M
Interest Income	$16M
Interest Expense	$1.6M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$36M
Income Before Tax	-$465M
Income Tax Expense	-$1.1M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$464M
Comprehensive Income Net Of Tax	-
Ebit	-$463M
Ebitda	-$427M
Net Income	-$464M

RXRX News

RXRX Profile

Recursion Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

RXRX $5.50 (+3.38%) Quote details